Glucagon-like peptide-1 (GLP-1) suppresses body fat mass via interleukin-6 (IL-6) and IL-1 acting in the brain - how and where?
Description: Aim:
Our long-term aim is to study the interactions between the immune system and metabolic function. We were first to show in 2002 and 2006 that lack of biological effects of endogenous interleukin-6 (IL-6; Wallenius V et al 2002, Nat Med 8:75-79; 885 citations in Google Scholar) or IL-1 (Garcia M et al Diabetes 55:1205-1213) causes mature onset obesity in mice, probably by increasing energy expenditure at the level of the central nervous system. In 2013, we found that brainstem glucagon-like peptide-1 (GLP-1) exerts its well known and clinically relevant anti-obesity effect by increasing the expression of IL-6 and IL-1 in the brain (Shirazi R et al 2013, Proc Natl Acad Sci, USA 110: 16199-16204). Our aim for the next 3-5 years is to investigate how and where in the brain the chain of events GLP-1 IL-6 (& IL-1) anti-obesity are exerted. We will prioritize IL-6 before IL-1.
We will systematically test a working hypothesis: We believe that enhanced expression of IL-6 in hypothalamic cells close to the ventricles, causes IL-6 release into the ventricle system. This IL-6 may then act on abundant IL-6 Receptor (IL-6R) on the ventricle side of tanycytes. Tanycytes are specialized glia cells located as gate keepers between the ventricles and the blood in the basal hypothalamus. These cells are part of the blood-brain barrier. This IL-6R activation could increase sensitivity to (and transport of) the anti-obesity hormone, leptin, that reaches the tanycytes from the blood side, and thereby explain how GLP-1 and IL-6 decrease obesity. IL-1 may act via a similar mechanism.
Plan:
We will use several complementary approaches:
• By using laser capture technique and in situ hybridization we will investigate in which nuclei of the hypothalamus and brainstem, and in which cells, GLP-1 analogues increases IL-6 mRNA. (Month 18.)
• By using an IL-6 promoter knock in mKATE reporter mouse that we recently developed, we will investigate in which parts of the brain and in which cell types that the IL-6 gene promoter is activated in response to GLP-1 analogue treatment. (There are no good antibodies for IL-6 immunohistochemistry.) (Month 12.)
• We will investigate where IL-6 is mediating the anti-obesity effect of GLP-1 analogues. This will be done by injection of a Tat-CRE construct to different parts of the brain of mice with LoxP sequences flanking crucial IL-6Rα gene exons. Thanks to the Tat, the CRE recombinase is taken up by cells, and the IL-6Rα production is inhibited. The effect of IL-6Rα depletion on food intake and body weight in response to injection of GLP-1 analogues can then be measured. (Month 24.)
• We will investigate if local periventricular IL-6Rα depletion by Tat-Cre injection to the ventricles of mice affects leptin sensitivity with regards to food intake, body weight, and body fat (Month 24).
• If we find that CSF side depletion of IL-6Rα decreases biological leptin sensitivity, we will investigate if phosphorylation of STAT3 in the mediobasal hypothalamus and uptake of labeled leptin by tanycytes are affected (Month 30).
• In clinical studies we will investigate if treatment with GLP-1 analogues to healthy humans and obese patients will cause increased levels of IL-6 (and IL-1) in the CSF as in rodents (Month 24).
• As a follow-up plan, we will investigate the site and mechanism of action of the GLP-1 mediator effect of IL-1 in a similar manner as for IL-6. This is of interest as IL-1 induces phosphorylation of the intracellular signal protein ERK, and ERK stimulation has been shown to enhance leptin actions on tanycytes (Month 60).
• Finally, we will study if IL-6 and IL-1 in the brain interact with GLP-1 to decrease obesity in germfree mice. We have shown that germfree mice have increased brain GLP-1 levels in addition to decreased fat mass. (Month 12.)
Importance:
Understanding the mechanism of action of a successful obesity treatment like GLP-1 analogues is likely to result in new and more refined tre
Funder: Vetenskapsrådet
Amount: SEK 4,000,000
Funding type: research
Funder scheme: Project grant
Start date: 2016-01-01
End date: 2019-12-31
Investigator: John-Olov Jansson (lead)
Institution: University of Gothenburg
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 2
Funder award ID: 2015-02477
OpenAlex ID: G2753324323
